Latest News and Press Releases

Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023

Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALLComplete responses observed in patients with CD19 negative disease No antigen negative relapse seen in...

Obe-cel, a potentially transformational treatment for relapsed/refractory (r/r) adult B-cell Acute Lymphoblastic Leukemia (ALL), on track for a Biologics License Application (BLA) submission to the US...

- Veronica Hersberger appointed as Senior Vice President, Medical Affairs- Miranda Neville promoted to Senior Vice President, Project Management and will continue to lead the obe-cel program LONDON,...

LONDON, July 18, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...

Long-term CAR T cell persistence is associated with durable responses in B-ALLObe-cel CAR T cells can persist in patients at levels sufficient to allow their isolation from blood samples, even years...

LONDON, June 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...

LONDON, June 20, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces...

At the highest dose 4 out of 4 PTCL patients achieved a response using the original manufacturing process (Process A)Ongoing complete metabolic responses in 2 out of 4 patients at 15 and 18-months...

LONDON, June 06, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, has posted...